Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Block 2 > Pharm > Flashcards

Pharm Flashcards

1
Q

pharmacology

A

study of substances interacting w/ living systems thru chemical processes (binding, activating, inhibiting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

pharmacokinetics. involves: Absorption vs Distribution vs Metabolism vs Excretion/elim

A

what body does to drug –> determines drug conc in body. drug from administration site to circ vs drug REVERSIBLY goes from circ to tissue vs aka biotransformation; drug modified by enzymes in various cells; active to inactive, active to active/toxic, inactive to active, unexcretable to excretable vs drug/metabolites IRREVERSIBLY elim from body by removing intact drug or removing drug that underwent biotransformation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pharmacodynamics. involves Mechanism of action

A

what drug does to body. specific biochem interaction where drug produces pharmacological effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

chemotherapy vs pharmaceutics vs pharmacogenomics vs pharmacognosy vs pharmacotherapeutics vs pharmacy vs therapeutics vs toxicology

A

using drugs to prevent and tx dz vs making drugs vs relationship b/w pt’s genetics and their response to drugs vs study drugs isolated from natural sources like plants and microbes vs using drugs to tx dz vs science involving prep, store, dispense, and use drugs vs using drugs to prevent and tx dz vs study of poisons and organ toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

drug resources: small molec drugs vs biologics vs biosimilars

A

natural (plants, microbes, animals, minerals), semi synthetic (chemically modifying from natural src), synthetic (made in chem lab) vs genetically engineered in living org vs biological product similar to FDA approved product; made from living organisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

excipient

A

inactive by themselves, goes w/ active ingredient for flavor, bulking/binding, improve manufacture/bioavailability/stability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

immediate release vs delayed release vs sustained/extended release vs targeted release vs oral disintegrating tablets (ODT)

A

conventional, release drug immediately vs release discrete portions some time after admin; enteric coated drugs protect envelope from stomach acid to move to GI tract –> good for acid labile drug vs control drug release for many hours –> slower absorption & longer duration vs release drug at/near intended physiologic site (can be IR or ER) vs disintegrates in saliva, no water needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

is SR/ER drug good for urgent situations?

A

nope

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

admin routes: enteral vs parenteral vs other

A

involves esophagus, stomach, sm/lg intest (PO, SL, PR) vs not involve GI tract (IV, IM, subq, IO) vs inhalation (most rapid), intranasal, intraventricular, topical, transdermal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

legend vs nonlegend drugs

A

rx, more harmful side effects –> don’t self medicate vs OTC, less harmful side effects –> can self medicate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

controlled and noncontrolled drugs criteria

A

based on med use, abuse potential, safety, dependence liability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Schedule I vs II vs III vs IV vs V controlled drugs

A

highest potential for abuse, no current accepted medical use –> only for research (ex: mj, LSD, heroin) vs high potential for abuse that could lead to physical/physiological dependence (ex: morphine, hydrocodone, amphetamines, cocaine) vs potential for abuse less than I and II that could lead to moderate/low physical dependence or high physiological dependence (ex: codeine, anabolic steroids) vs low potential abuse less than III (ex: alprazolam, diazepam, clonazepam, carisoprodol, tramadol) vs low potential for abuse (ex: combination products w/ limited amts of narcotics, pregablin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

indication vs off label use

A

med has been evaled for safety and efficacy by FDA –> approved vs rxing meds that has not been FDA approved

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

adverse drug event vs rxn/side effect

A

harm to pt from drug exposure d/t drug error; you don’t expect rxn from drug vs pt experiences rxn from drug exposure even if drug admin appropriately; you expect rxn from drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

relative vs absolute contraindication

A

only rx drug when benefit < risk vs AVOID b/c life threatening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

black box warning

A

most severe warning from FDA about drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

category A vs B vs C vs D vs X

A

good to go for preg vs no evidence in risk of animal studies w/o controlled studies of preg OR or adverse effects in animal studies w/o controlled human studies vs only give if benefit > risk; evidence of risk on animals (teratogenic, embryocidal) w/o controlled human studies OR no reproduction studies avail for animals or humans vs evidence of fetal risk but benefit > risk vs evidence of fetal risk, risk > benefit –> don’t give

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

dz oriented evdience vs pt oriented evidence that matters

A

hard data; answer questions about etiology, pathophysiology, pharmacology; intermediatae or surrogate outcome vs soft data; answers questions that physicians and pts care about and outcome may change practice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how to rx CIII-V vs noncontrolled drugs vs CII drugs

A

expire 6mo after it’s written, 5 refills up to 6mo period vs no fed specific time limit, VA expires 12mo from date of issue vs no expiration date, no refills, “do NOT fill before [date]”, up to 90d supply

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How is drug admin route determined?

A

Drug properties (water/lipid solubility, ionization) and therapeutic objective (onset, duration, site of action)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Factors influencing drug absorption

A

pH of area (nonionized = penetrate cell membrane), AUI/BPI; blood flow to absorption site (drug to intestines > stomach b/c intest has more vasculature), total SA for absorption, drug exposure to absorption surface (drug to GI = not good if pt has diarrhea)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

1st pass effect/metabolism

A

Drugs absorbed from gut to liver via hepatic vein before entering circ —> converted to inactive metabolites —> dec bioavailability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

bioavailability. How to calculate it?

A

Rate and extent to which drug reaches circ. How much drug administered, how much drug absorbed (if 100mg of drug = admin, but 70mg of drug = absorbed —> bioavailability = 70%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When are 2 pharmaceutical equivalents vs bioequivalents?

A

Have same active ingredient, identical in strength/conc/dose/admin route vs bioavailability of both = not significantly diff

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Bioequivalent vs biosimilar based on size and origin

A

Smaller; chemically synthesized vs bigger; made from living organisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Factors that affect drug distribution

A

Blood flow (more vascular = better), capillary permeability (blood brain barrier), binding of drugs to plasma and tissue proteins, size (ex: heparin = too big) and lipophilicity of drug (lipophilic drugs can move thru cell membrane better; hydrophilic drugs can’t —> pass thru slit jxns)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

vol of distribution

A

vol of liquid in which drug needs to be dissolved to mimic same plasma conc; calc by V = D/Co (V = vol of distribution, D = amt of drug in body/total dose, Co = plasma conc at time zero)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

one vs two vs multicompartment model of distribution

A

whole body = 1 compartment –> applicable to drugs that distribute to tissue simul or stay in plasma and elim immediately begins; reality: N/A for majority drugs vs whole body = 2 compartments –> central compartment = init vol of distribution, final compartment = vol of distribution after equil –> applicable to drugs that distribute to tissue slowly or equilibriate slowly b/w plasma and tissue; reality: applicable for majority drugs vs drugs that distribute into mult tissues at significantly diff rates (drugs taken up by vessel rich groups –> muscle –> adipose); so many diverse rates –> drug may never reach equil b/w plasma and tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

where can metab/biotransformation occur?

A

liver –> 1st pass effect, has microsomal enzymes; GI tract, lungs, kidney, brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

ex of phase I vs phase II biotransformation rxns

A

hydrolytic rxns, reductive rxns, oxidative rxns (HRO) vs conjugation rxns, acetylation, glucuronide formation, sulfation, UGTs –> all make it highly soluble

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

other names and fxns of P-glycoprotein 1 (PGP1) (drug transport protein)

A

aka multidrug resistance protein 1 (MDR1) or ABC binding cassette sub family B member 1 (ABCB1). Transport drugs back into GI tract, back out of the brain (part of BBB), or into proximal tubule for excretion; uses 2 ATP to pump out 1 molec of drug; lipo>hydrophilic drug preference; protects pt (pumps foreign substances out)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

drug transport protein affects?

A

ADME

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

renal elim

A

drug elim thru urine. 1) glomuerular filtration: plasma binding of drug, measure GFR –> 2) active and carrier mediated tubular secretion –> 3) passive tubular reabsorption of nonionized WA/B, ionized WA/B = trapped in nephrons and get elim thru urine, feces, biliary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

biliary and fecal elim

A

drug elim thru liver. 1) active drug and metabolite secretion into bile –> 2) some drugs/metabolites cn be reabsorbed from intestine to body by making them less hydrophilic via gut microbes => enterohepatic recycling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

1st vs 0 order/nonlinear kinetics of elim

A

most drugs use 1st order kinetics; clearance mechanisms = NOT saturable; rate only depends on plasma drug conc; looks like straight line on semilog plot (like MM enzyme plot); rate of admin > rate of elim b/c plasma conc = too low –> as drug = still admin, rate of elim inc and rate of admin = constant –> rate of admin = rate of elim vs for carrier mediated elim; enzymes saturated by unbound drug conc –> plasma drug conc > Km; rate = independent of drug conc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

drug Clearance defs and eqn

A

body’s efficiency in elim drug from circ; vol of plasma from which drug = removed per unit time or rate of drug elim from body relative to plasma drug conc. CL = V/Css (CL = clearance, V = rate of elim, Css = steady state conc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

what is CLtotal vs extraction ratio?

A

total drug clearance from body from all organs vs fraction of drug cleared by organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Css. how to reach it?

A

drug lvls = constant in plasma and target tissue. takes 4-5 half lives to reach Css; when drug = 1st order kinetics, rate of admin > rate of elim b/c plasma conc = too low –> as drug = still admin, rate of elim inc and rate of admin = constant –> rate of admin = rate of elim

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

what does Css depend on?

A

drug dose administered, bioavail, drug clearance or half life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

2 types of half life: 1/2 life of elim vs 1/2 life of accumulation

A

time required to reduce drug amt by 1/2 after dosing stops vs time required to inc drug amt by 1/2 during constant infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

standard dose vs therapeutic range vs drug selectivity

A

based on trials of healthy volunteers with average ADE –> not suitable for q pt –> individualizes efficacy and toxicity/adverse effects vs Drug conc when pharmacologic response shows desired effects & no adverse effects/toxicity vs ability of drug to show desired effects & minimize adverse effects/toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

loading vs maintenance dose

A

single dose of drug to reach desired plasma conc as fast as possible, followed by MD; base on therapeutic range; usually for IV but if not –> consider bioavailability vs amt of drug given over time to maintain desired plasma conc; based on therapeutic range; rate of drug going in = going out

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

cont IV infusion vs intermittent dosing for Css

A

plasma conc inc till it reaches equil –> rate of drug going in = out vs when conc v time curves = superimposable

44
Q

dosing interval

A

The frequency of intermittent drug administration, based on the drug’s half-life

45
Q

vancomycin

A

glycoside abx; IV active against gram pos, orally active against C diff b/c not absorbed in GI tract; time dependent bacterial killing –> need min conc for therapeutic effects

46
Q

what is a drug interaction?

A

when 1+ drugs react w/ e/o, food/drinks, or medical conditions that change PK, PD, metab, or drug properties; can be harmful or helpful

47
Q

types of drug interaction: drug-drug vs drug-food vs drug-dz aka drug-medical condition interaction vs therapeutic duplication vs pharmaceutical interaction

A

2+ drugs interact w/ e/o, involves CYP450 vs food/drink changes how drug behaves; alc inc sedatives, Ca2+ chelates doxycycline vs pseudoephedrine inc bp vs 2 meds for same indication vs incompatible chem rxn –> precipitate

48
Q

what’s special about CYP2C19?

A

main metabolic pathway susceptible to genetic polymorphisms influenced by race

49
Q

how do statins lower chol? what are their adverse effects?

A

inhibit HMG CoA reductase. myalgia/muscle pain, myopathy, weakness, elevated CK, rhabdomyolysis

50
Q

herbal supplements. example?

A

not FDA approved, no studies or tests required –> minimal PK/PD studies to support use; USP certification = voluntary. St John’s wort

51
Q

which enzyme mainly converts prodrug to active drug?

A

CYP450

52
Q

polypharmacy

A

anyone taking 1+ drug and with 1+ comorbidity

53
Q

who’s at risk for drug interactions?

A

age, severity of dz, long term dz

54
Q

characteristics of drugs that more likely to interact

A

narrow therapeutic window, metab to active metabolite, lower bioavail, metabolized by on CYP450 or by 1 pathway, red flag drugs

55
Q

digoxin

A

effluxed into the intestine & not absorbed; lvls dec when PGP inc (lvls inc when PGP dec) b/c not absorbed; non therapeutic index drug –> requires monitoring

56
Q

theophylline

A

asthma and COPD tx; narrow therapeutic index –> requires monitoring

57
Q

synergism vs additive vs antagonism

A

sum of responses for greater effect vs sum of individual responses vs opposite effects, reduction of total effects

58
Q

some drugs don’t fit drug-receptor model. what do they do?

A

physical actions –> osmotic diuretics (inc urine osmolarity; urea, mannitol) or osmotic cathartics (inc intestinal osmolarity; MgSO4). chemical actions –> antacids, chelating agents

59
Q

what proteins can be drug targets?

A

structural proteins, circulating proteins, molecular transporters

60
Q

specificity of receptor’s binding site = based on?

A

3D structure, shape, charge, chemistry of environ (hydrophobic/philicity, pKa)

61
Q

transduction in receptor-ligand binding

A

drug binds to receptor –> alters cellular components linked w/ receptor –> produces response

62
Q

receptor-ligand binding = d/t which IM forces?

A

attractive forces: reversible or irreversible/covalent; repulsive forces –> conformational change

63
Q

drug selectivity = determined by?

A

specificity for receptors (cisplatin interacting w/ DNA, omezaprole interacting w/ proton pumps) and for receptor-effector coupling (Ca2+ channel blockers work for pacemaker cells > ventricular muscle cells)

64
Q

agonist (full vs partial vs inverse). antagonist (competitive vs noncompetitive)

A

activates receptor and keeps it in active form (causes maximal activation vs partial activation; shift dose-response curve down; can act as partial antagonist if full agonist = present => mixed agonist-antagonists vs reduces receptor activity). prevents receptor from activation but preserves activity (reversibly blocks active site; can be overcome by high substrate conc; inc Kd, dec potency, no effect on efficacy vs ir/reversibly binds allosteric site or irreversibly/covalently binds active site; inc Kd, no effect on potency, dec efficacy)

65
Q

type I drug receptors = ion channels. describe the 3 subtypes

A

ligand gated (ligand binds to specific site on receptor –> alters pore size –> ions pass thru; ex: asp/glu = excitatory aa receptors, GABA/glycine = inhibitory aa receptors). voltage gated (change in transmembrane potential –> depolarization –> opens channel for ions to pass thru; ex: Na+, K+, Ca2+ channels). secondary msgr (modulated by G protein coupled receptor)

66
Q

type II drug receptors = G protein coupled receptors

A

7 transmembrane regions: extracellular domain binds to ligand, intracellular domain binds and activates G protein; G protein has 3 subunits: alpha, beta/gamma

67
Q

Gs vs Gi vs Gq vs G12/13

A

activates Ca2+ channels, activates adenylyl cyclase –> inc cAMP vs activates K+ channels, deactivates adenylyl cyclase –> dec cAMP vs activates PLC –> inc IP3 –> inc Ca2+ vs activates Rho for PLT aggregation

68
Q

type III drug receptors = transmembrane enzymatic receptors

A

single membrane spanning unit + intracellular domain has cyto MOA –> membrane bound and cytosolic; receptors may dimerize upon activation; ex: kinase, phosphatase, guanylyl cyclase

69
Q

can AC and GC be metab by PDE? can they be activated by G protein?

A

yes. yes

70
Q

type IV drug receptors = intracellular

A

target intracellular enzymes (vit K), transcpxn factors (steroids/cortisol, glucocorticoids/prednisone), structural proteins (abx targeting 50/30S ribosomes), nuclear receptors (glu)

71
Q

drug-receptor occupancy theory

A

When sufficient amount of receptors = bound by a drug –> cumulative effect of receptor occupancy = more apparent as a cell response
Response in many cells –> bigger response observed in organ or organism/patient

72
Q

how to find dissociation constant Kd b/w ligand/receptor interaction. how to find binding affinity/% bound?

A

[L][R]/[LR]. binding affinity = LR/Ro (LR = bound receptor, Ro = total amt of receptor); higher binding affinity –> low L

73
Q

graded dose-response vs quantal dose-response relationship

A

dose-response curve for individual –> response = graded, depends on dose vs dose-response curve for pop –> response = present or absent

74
Q

2 parameters for graded dose response relationship: potency (EC50) vs efficacy (ECmax)

A

drug conc where drug causes 50% of maximal response vs maximal response produced by drug

75
Q

3 parameters for quantal-dose relationship: median effect dose (EC50) vs median toxic dose (TD50) vs median lethal dose (LD50)

A

drug conc where drug causes 50% of maximal response vs drug conc where 50% of pop have toxic effects; indicators of toxicity vs tested on animals; indicators of toxicity

76
Q

what does it mean for drug to have high TI value?

A

wide therapeutic index –> desired effects curve and toxic effects curve don’t overlap –> excess drug = okay to give for therapeutic effects

77
Q

nonreceptor antagonists: chemical vs physiologic

A

binds to agonist and neutralizes it before it can work vs produces effect that’s opposite to agonist effect

78
Q

spare receptors

A

extra receptors to induce response when not enough main receptors = occupied; occupancy = NOT related to strength of response (ie. you don’t need to fill all main receptors to induce response, just enough to pass threshold)

79
Q

clinical ex of spare receptors: insulin receptors vs heart

A

1% receptor occupancy required for max response –> 99% = spare –> large fxnal reserve vs 90-95% receptor occupancy required for max response –> 5-10% = spare –> little fxnal reserve

80
Q

how do spare receptors act in presence of low vs high conc of noncompetitive antagonists?

A

still get max response vs can’t get max response

81
Q

how do agonists shift curve low vs high conc of noncompetitive antagonists?

A

shifts curve down like competitive antagonist vs shifts curve down and to right

82
Q

how do allosteric activators shift curve?

A

up and to left

83
Q

osteoporosis

A

inc bone resorption, fx risk; dec bone formation, bone mass; microarchitectural disruption

84
Q

sunshine vs vit D vs low Ca2+ vs PTH vs calcitonin

A

inc endogenous vit D3/cholecalciferol in skin –> inc vit D/calcitriol –> inc bone turnover vs prohormone vit D –> calcidiol –> calcitriol (active) –> inc bone turnover by inc osteoblasts and clasts; D2 = ergocalciferol, D3 = cholecalciferol vs inc PTH and calcitriol to inc bone resorption vs low exogenous PTH –> inc bone turnover, high exogenous PTH –> bone resorption vs inhibit clasts –> dec bone resorption

85
Q

estrogen vs GH

A

dec clasts –> indirectly inc bone formation vs inc blast activity –> inc bone formation

86
Q

primary vs secondary risk factors of osteoporosis

A

inc age, previous fxs, fhx, cauc/asian, low body wt, menopause vs steroids/heparin/excess thyroid hormones, alc/caffeine/tobacco, inactivity, diet

87
Q

universal recs for osteoporosis

A

adeq intake of Ca2+ (calcium carbonate/citrate, milk/yogurt/cheese), adeq intake of vit D (D2/3, sun, fortified milk), wt bearing exer, fall prevention, stop smoking/alc

88
Q

which 3 bones DEXA measures?

A

femoral neck, total hip, lumbar spine

89
Q

paget’s dz of bone

A

localized dz d/t uncontrolled osteoclastic bone resorption –> bone formation = unorganized –> bone pain, deformity, fx, arthritis

90
Q

sxs of Paget’s

A

mostly asx; bone pain, deformity, fx, arthritis, hypercalcemia, osteosarcoma

91
Q

how to tx Paget’s?

A

adeq intake of Ca2+ and vit D, bisphosphonates (zoledronic acid = tx of choice), NSAIDs, calcitonin

92
Q

chemical mediators of inflamm

A

histamine, complement proteins, eicosanoids (metabolites from arachidonic acid), cytokines (IL1, TNF alpha), ROS/RNS

93
Q

How does arachidonic acid become eicosanoids?

A

TNF alpha stimulates PLA2 –> PLA2 releases AA from phospholipid membrane –> prostaglandins sensitize nociceptors –> promote blood flow to injured tissues –> inc leuks, edema, inflamm

94
Q

COX/prostaglandin H synthase has 2 enzymatic activities: cyclooxygenase vs peroxidase

A

catalyzes O2-dep cyclization of AA to PGG2 vs catalyzes reduction of PGG2 to PGH2

95
Q

COX1 vs COX2 vs COX3

A

protection and maintenance: vasc homeostasis, maintenance of GI and renal blood flow and fxn, PLT fxn vs inflamm, fever, pain, mitogenesis vs potential binding site of acetominophen

96
Q

5 manifestations of inflamm

A

heat, swelling, redness, pain, loss of fxn

97
Q

examples of COX inhibitors

A

NSAIDS: ASA (salicylate), ibuprofen (like Motrin/Advil; propionic acid derivative), indomethacin (acetic acid derivative). COX2 inhibitors: celecoxib. acetaminophen = NOT a trad NSAID b/c not fully antiinflamm and structurally diff

98
Q

antipyretics and analgesics tx?

A

rheumatic fever, rheumatoid arthritis, and inflammatory joint conditions

99
Q

trad NSAIDs can tx?

A

 tx pain and fever
 relieve inflammation for arthritic d/o and injuries
 slow progression of Alzheimer’s
 dec risk of colon ca

100
Q

ASA adverse effects

A

epigastric distress, ulcer, hemorrhage, resp depression, Reyes, hypersensitivity

101
Q

Reyes syndrome

A

occurs when ASA given to children w/ viral infxn –> fatal fulminating hepatitis w/ cerebral edema

102
Q

how does ASA affect PLTs?

A

 TxA2 –> inc plt aggregation
 PGI2 –> dec plt aggregation
 ASA –> dec COX1 in plts –> dec TxA1 in plts –> dec plt aggregation –> anti-thrombogenesis –> prophylaxis of MI and stroke

103
Q

how does ASA affect kidneys?

A

PGE/I2 maintain renal blood flow. ASA –> dec COX –> dec PGE/I2 –> dec renal blood flow –> renal dysfxn –> water/salt retention

104
Q

acetaminophen key points

A

not a NSAID; can inhibit COX3 –> tx mild pain and fever; OD = liver injury (responsible for 46% of liver failure in USA) –> N-acetylcysteine as antidote –> cys –> glutathione –> detox toxic metabolites of acetominophen

105
Q

propionic acid derivatives key points

A

ibuprofen = potent NSAID; reversibly inhibits COX. naproxen = single enantiomer and more potent than ASA. ketoprofen inhibits both COX and lipoxygenase. flurbiprofen for ophthalmic. oxaprozin has long 1/2 life, mildly uricosuric –> tx gout

106
Q

acetic acid derivative key points

A

indomethacin and diclofenac = potent; indomethacin for patent ductus arteriosus; diclofenac for arthritis and opththalmic, has serum aminotransferases. sulindac dec colon ca. etodolac = COX2 selective

107
Q

oxicam derivative key points

A

piroxicam has long 1/2 life, tx arthritis. meloxicam = COX2 selective

Block 2 (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions